Your legs give out
when you walk —
your spine is why.

The natural history of neurogenic claudication is variable but trends toward progression in most patients over years. The underlying pathology — ligamentum flavum hypertrophy, facet overgrowth, disc collapse — progresses slowly and continuously. The walking tolerance that deteriorates typically does not spontaneously recover. Some patients have a stable plateau for years; others progress steadily. The important clinical point is that neurogenic claudication does not lead to paralysis or cauda equina syndrome in the way that acute disc herniation can — it is a chronic, progressive functional limitation rather than an acute neurological emergency. This gives room for conservative management before surgery. But a patient whose walking distance is progressively shrinking and whose quality of life is significantly limited has a condition that responds well to surgical decompression — and the longer decompression is delayed, the longer nerve roots have been under sustained compression.

Not always — and this is one of the most important questions for patients with neurogenic claudication to ask. Fusion is indicated when there is significant segmental instability — a vertebral slip that changes with flexion and extension, or deformity that requires correction. For stenosis without instability — the most common presentation — decompression alone (laminectomy) is appropriate and avoids the recovery burden, adjacent segment disease risk, and permanent structural alteration that fusion carries. For stenosis with spondylolisthesis, TOPS is now an alternative to fusion that achieves stabilization while preserving motion and significantly outperforms fusion in clinical outcomes data. A surgeon who offers only fusion for neurogenic claudication is offering an appropriate procedure in some cases — but not presenting the full range of options. An independent evaluation specifically determines whether your anatomy is suitable for decompression alone or for TOPS before recommending fusion.

For most patients, relief of the characteristic walking-related leg symptoms is rapid — within days of surgery in many cases. The mechanical compression is removed, and the cauda equina begins recovering immediately. Walking distance typically improves dramatically in the first weeks after decompression. The full extent of improvement continues over months as nerve root inflammation resolves and neural tissue recovers from chronic compression. One important caveat: if nerve roots have been severely compressed for a long time — particularly if there is motor weakness or significant numbness preoperatively — the recovery of those specific deficits may be incomplete even after successful decompression. The pain and functional limitation of neurogenic claudication almost always responds well; longstanding motor weakness or dense numbness may only partially recover. This is one of the arguments against waiting too long with progressive symptoms.

Yes — and this is clinically important. Both conditions increase in prevalence with age, and a 70-year-old patient with peripheral arterial disease and lumbar stenosis may have both contributing to walking limitation. The challenge is determining which is the primary driver and which is incidental. The clinical features described on this page — shopping cart sign, relief specifically with sitting vs. stopping, bilateral leg onset pattern, skin and pulse examination, cycling tolerance — are the tools for clinical differentiation. A vascular surgery consultation with ABI and duplex ultrasound, combined with MRI of the lumbar spine and a careful clinical examination, establishes the relative contribution of each. When both are significant, both may require treatment — typically vascular revascularization first, then spine surgery if walking limitation persists.

TOPS (Total Posterior Segment replacement) is an FDA Breakthrough Device designed specifically for degenerative spondylolisthesis with stenosis — the diagnosis that most commonly produces neurogenic claudication with instability. Standard fusion eliminates all motion at the treated segment, which stabilizes the slip but creates a rigid construct that transfers mechanical stress to adjacent levels and produces adjacent segment disease over time. TOPS stabilizes the slip through a controlled-motion device rather than rigid fixation — allowing the level to move within defined limits rather than not at all. In the FDA randomized controlled trial, TOPS produced 77% overall clinical success versus 24% for fusion at 2 years, with greater walking distance, less residual leg pain, and superior functional outcomes. The device requires specific training and certification. Dr. Katsevman is on the official TOPS surgeon locator — most spine surgeons treating spondylolisthesis are not certified for TOPS and will recommend fusion as the default, simply because it is the procedure they perform.